Prostate Cancer - Results from #1140

PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. April 2, 2024

Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study. April 2, 2024

The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective. April 2, 2024

Advances in Radioligand Theranostics in Oncology. April 2, 2024

Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials. April 2, 2024

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. April 1, 2024

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. April 1, 2024

The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016. April 1, 2024

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. April 1, 2024

Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course? April 1, 2024

Military service and health-related quality of life among gay and bisexual prostate cancer survivors: Results from the Restore -2 study. March 31, 2024

Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer. March 29, 2024

The Current Therapeutic Landscape for Metastatic Prostate Cancer. March 29, 2024

Exploring Information Seeking Anxiety Among Localized Prostate Cancer Patients. March 29, 2024

Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. March 29, 2024

Racial differences in postpandemic trends in prostate-specific antigen screening. March 29, 2024

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. March 28, 2024

A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer. March 28, 2024

Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions. March 28, 2024

Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression. March 28, 2024

Page 58 of 1436